Journal
BRAIN STIMULATION
Volume 3, Issue 3, Pages 177-180Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.brs.2009.08.001
Keywords
bupropion; resting motor threshold; repetitive transcranial magnetic stimulation; cortical excitability
Categories
Funding
- National Institute of Mental Health (NIMH) [R01 MH069886]
- National Alliance for Research on Schizophrenia and Depression (NARSAD), NIMH
- Greenwall Foundation
- Advanced Neuromodulation Systems/St. Jude Medical
- AstraZeneca
- GlaxoSmithKline, Inc.
- Boehinger Ingelheim
- Neuronetics
- Janssen
- Smith Kline
- Wyeth
- Shaw Science
- Tetragenex
Ask authors/readers for more resources
Background Bupropion is associated with a dose-related increased seizure risk. This effect could correlate with a change in motor cortex excitability. Transcranial magnetic stimulation (TMS) can assess changes in motor cortical excitability by measuring resting motor threshold (RMT). Methods RMT was determined before and during 2 weeks concomitant administration of bupropion at two different doses (150 mg/d and 300 mg/d) in a 41-year-old woman enrolled in a study of repetitive TMS (rTMS) for the treatment of depression. Results RMT was significantly lower when the patient took 300 mg/d of bupropion compared with no bupropion and 150 mg/d of bupropion. When bupropion was reduced to 150 mg, RMT returned to the premedication level. Conclusions Bupropion 300 mg/d increased cortical excitability as demonstrated by decreased RMT. This finding emphasizes the importance of assessing RMT regularly during rTMS treatment, especially in the context of new or changed doses of medications. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available